Table 6.

Risk for severe obstetrical hemorrhage and hypertension-associated or neurologic morbidity based on the timing of SARS-CoV-2 infection

Outcome by timing of infection	Adjusted ORa (95% CI)
Severe obstetrical hemorrhageb
Active SARS-CoV-2 infection	1.71 (0.85–3.10)
Resolved SARS-CoV-2 infection	1.89 (0.83–3.74)
SARS-CoV-2 negative	Ref
Hypertension-associated or neurologic morbidityc
Active SARS-CoV-2 infection	1.09 (0.77–1.54)
Resolved SARS-CoV-2 infection	1.07 (0.69–1.60)
SARS-CoV-2 negative	Ref

Data are presented as adjusted odds ratios with 95% confidence intervals.

CI, confidence interval; HELLP, hemolysis, elevated liver enzymes, low platelet count; OR, odds ratio; Ref, reference interval.

^aModels adjusted for maternal age, body mass index, race, ethnicity, parity, insurance type, neighborhood-level characteristics, hospital location, comorbid conditions, gestational diabetes, hypertensive disorders of pregnancy (gestational hypertension or preeclampsia), mode of delivery, and gestational age at delivery

^bIncludes patients with at least 1 of the following: obstetrical hemorrhage requiring transfusion of ≥4 packed red blood cells, uterine artery embolization, or peripartum hysterectomy

^cIncludes patients with at least 1 of the following: eclampsia, stroke, severe hypertension requiring antihypertensive therapy, or HELLP syndrome.

Gulerson. Severe maternal morbidity associated with COVID-19. Am J Obstet Gynecol MFM 2022.